The analysis notes the women-only result is post hoc and that women also lose more on tirzepatide, framing Novo's move as a play for OB-GYN prescribers.
Recap by typeshit. Full story at Business Model Analyst.
She talks with Annika Urban about combining GLP-1 treatment with behavioral coaching and telehealth care.
An opinion piece drawing on Sabrina Strings to tie GLP-1 culture, celebrity ads and Ozempic-friendly menus to class and belonging.
Oddo moved to DKK 305 and HSBC to DKK 280. Novo also shared a CagriSema subgroup analysis showing women lost 25% of body weight at 68 weeks.
MUSC Health suggests the familiar ABCs of heart health may change, with GLP-1 medications now part of cardiovascular prevention for some patients.
Lilly's retatrutide is still in development with no FDA approval, yet CBS investigators found vials labeled 'reta' easy to buy across the internet and in shops.
A $90 Brooklyn vial held a filler used in lip balm plus 13 bacteria colonies, University of Iowa testers said. Two online orders shipped with no consultation.
Loading…